entertainment -WSS

entertainment

author：fashion 2025-09-05 09:20:04 - browse：587

The New York Stock Exchange (NYSE) — Spencer Platt/Getty Images

Biohaven Pharmaceuticals said Wednesday that a new type of experimental medicine reduced levels of a disease-causing immune molecule by up to 37% in an early-stage study of human volunteers — a result that the company called “positive” as a proof of concept but that also fell short of investor expectations.

The drug, called BHV-1300, belongs to a new class of antibody medicines that shuttle harmful proteins to the liver so they can be removed from the body. BHV-1300 is specifically designed to reduce levels of an autoantibody called IgG that is implicated in rheumatoid arthritis, myasthenia gravis, and other autoimmune disorders.

In its Phase 1 study, Biohaven tested four escalating doses of BHV-1300 in healthy volunteers, showing a reduction in levels of IgG of 5%, 15%, 30%, and 37%, respectively, the company said. The reductions in IgG levels, which occurred relatively quickly in just four to five days, did not cause significant, adverse changes in liver enzyme levels, Biohaven added — an important safety check given the mechanism of the drug.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： NASA releases new images of 'fingerprint

WSS

Biogen shutters digital health group, ends Apple study, in cost cutting move

NASA releases new images of 'fingerprint

Covid vaccines: Private market messier than government rollout

Paxlovid should be available without a positive Covid test

Did you have Obamacare on your GOP debate bingo card?

Cigna to pay $172 million to settle Medicare Advantage fraud probe

hotspot

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

23andMe had bad news about my health. I wish a person had delivered it

NASA releases new images of 'fingerprint

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Palestinian attacker wounds 8 in Tel Aviv as Israel presses on with West Bank operation

In age of alternative facts, a scholarly course on calling out crap

Cigna to pay $172 million to settle Medicare Advantage fraud probe

The high cost of giving birth even with insurance

US ambassador visits Wall Street Journal reporter detained in Russia on charges of espionage

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

FDA seeks to regulate lab

hotspot

A timeline of the missing Titanic tourist submersible

Brazil's Neymar fined $3.3 million for illegal artificial lake at mansion outside Rio

Intercept Pharmaceuticals sells itself for less than $1 billion

Churchill Downs extends trainer Bob Baffert's ban through 2024

Noem? Reynolds? A very early look at the Republican 'veepstakes'

After a drawn out lobbying fight, ARPA

hotspot

entertainment

focus

focus